Robert Menardi, DVM, provides extensive experience and knowledge to the company that offers Synovetin OA
Exubrion Therapeutics has named Robert Menardi, DVM, its chief veterinary officer. He will manage the company’s veterinary technical education and outreach programs, plus serve as the subject matter expert for members of the veterinary field.
According to a company release,1 Exubrion offers Synovetin OA—canine elbow pain treatment that enhances mobility and provides proven relief for up to 1 full year. The treatment is now available in more than 50 treatment centers across the US, as additional clinics continue to acquire it.
“We’re very excited to have someone with such extensive veterinary technical experience join our team,” expressed Peter Selover, Exubrion CEO, in the release.“ As our product becomes more available nationwide, we are fortunate to have someone with Dr. Menardi’s breadth of experience lead our veterinary services.”
Previously, Menardi served in a comparable position at Canopy Animal Health in Duluth, Georgia. Before that, he fulfilled various roles at Merial Limited (now Boehringer-Ingelheim Animal Health) starting in 2002. He was first a technical services veterinarian, then over the following 17 years became director of technical marketing; director of field veterinary services, operations, and professional development; director of pet vaccines marketing; and director of veterinary technical solutions.1
What’s more, before Merial, Menardi served as a practicing veterinarian in Eagle River, Alaska, and Flagstaff, Arizona after earning his bachelor’s and DVM degrees at Colorado State University.
“I’m excited to join the growing team at Exubrion,” Menardi commented. "Veterinary medicine needs more companies offering new, unique medical solutions to meet unmet pet needs. Exubrion, and the Synovetin OA product, are bringing veterinarians and their patients a truly new, convenient, and long-lasting solution for chronic elbow pain and inflammation.”
Dr. Robert Menardi joins Exubrion Therapeutics. News release. Exubrion Therapeutics. May 25, 2022. Accessed May 26, 2022.